The FREEDOM COVID Anticoagulation Strategy Randomized Trial - report from ACC2023

Professor Gregg Stone explains the results of the FREEDOM COVID Anticoagulation Strategy Randomized Trial. The main conclusions are among non-critically ill pts hospitalized with COVID-19, at 30 days the lower incidence of the primary outcome for therapeutic dose compared with prophylactic dose did not reach statistical significance. However, significantly fewer pts treated with therapeutic-dose died or required endotracheal intubation within 30 days. Outcomes with therapeutic-dose enoxaparin and apixaban were similar, and bleeding was infrequent with all three regimens. Based on these findings, the use of therapeutic-dose anticoagulation may improve outcomes in non-critically ill patients hospitalized with COVID-19 who are at increased risk for adverse events but do not yet require ICU level-of care. Video: https://medicaldigest.org/scientific-contents/interview:freedom-covid-anticoagulation-strategy-randomized-trial